lapatinib / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

51 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
NCT00078572: Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

Completed
3
408
US, Canada, Europe, RoW
capecitabine, lapatinib (GW572016)
GlaxoSmithKline
Breast Cancer
04/06
02/10
NCT00075270 / 2004-001999-40: Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

Completed
3
580
US, Canada, Europe, RoW
Paclitaxel, GW572016 (Lapatinib)
GlaxoSmithKline
Neoplasms, Breast
10/06
03/12
NCT00320385: Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P3 data
Jun 2012 - Jun 2012: P3 data
Completed
3
296
US, Canada, Europe, RoW
Lapatinib, Tyverb, Tykerb, Trastuzumab, Herceptin
GlaxoSmithKline
Neoplasms, Breast
06/07
10/10
NCT00073528 / 2004-003928-35: Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Checkmark P3 data-SABCS
Dec 2011 - Dec 2011: P3 data-SABCS
Completed
3
1286
Europe, Canada, US, RoW
Lapatinib, GW572016, Letrozole, Placebo
Novartis Pharmaceuticals
Breast Neoplasms
06/08
03/18
NCT00272987 / 2005-003432-22: ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Terminated
3
63
Europe, US
lapatinib, paclitaxel, trastuzumab
Novartis Pharmaceuticals
Neoplasms, Breast
07/09
10/19
Neo ALTTO, NCT00553358 / 2006-000564-81: (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Checkmark Lapatinib with trastuzumab for HER2-positive early breast cancer
Aug 2014 - Aug 2014: Lapatinib with trastuzumab for HER2-positive early breast cancer
Checkmark SABCS 2013
Dec 2013 - Dec 2013: SABCS 2013
Checkmark Neoadjuvant lapatinib and/or trastuzumab
More
Completed
3
455
Europe, Canada, RoW
Lapatinib, Trastuzumab, Paclitaxel
Novartis Pharmaceuticals, Breast International Group, SOLTI Breast Cancer Research Group
Neoplasms, Breast
05/10
12/19
NCT00281658: Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Checkmark Biomarker data
Jul 2014 - Jul 2014: Biomarker data
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark
More
Completed
3
444
RoW
Lapatinib (GW572016) oral tablets, Paclitaxel infusion, Placebo
Novartis Pharmaceuticals
Neoplasms, Breast
06/10
11/21
2005-003926-24: A randomized, multicentre, open-label Phase III study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with metastatic breast cancer whose disease has progressed on trastuzumab-containing regimens

Completed
3
270
Europe
lapatinib, trastuzumab, GW572016, Film-coated tablet, Powder for solution for infusion, Herceptin
GlaxoSmithKline R&D Ltd, GlaxoSmithKline, S.A., GlaxoSmithKline Research and Development Ltd
Metastatic breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT00558103 / 2006-006537-40: Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Checkmark P2 data: HER2+ IBC
Dec 2012 - Dec 2012: P2 data: HER2+ IBC
Checkmark P2 data
Jun 2012 - Jun 2012: P2 data
Checkmark P2 data - ASCO
More
Completed
3
163
US, Canada, Europe, RoW
lapatinib, Tykerb, Pazopanib, Votrient
GlaxoSmithKline
Neoplasms, Breast
05/11
12/11
GeparQuinto, NCT00567554 / 2006-005834-19: Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

Checkmark SABCS 2014
Dec 2014 - Dec 2014: SABCS 2014
Checkmark In HER2-positive breast cancer pts
Aug 2014 - Aug 2014: In HER2-positive breast cancer pts
Checkmark Results from the GeparQuinto study (GBG 44)
More
Completed
3
2600
Europe
epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel, paclitaxel + everolimus (RAD001), epirubicin - cyclophosphamide / docetaxel + trastuzumab, epirubicin - cyclophosphamide / docetaxel + lapatinib
German Breast Group, AGO Study Group
Breast Cancer
08/11
10/15
NCT00374322 / 2005-005186-10: Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Checkmark ASCO-2013
May 2013 - May 2013: ASCO-2013
Checkmark
Dec 2012 - Dec 2012: 
Checkmark P3 data: SABCS 2012
More
Completed
3
3166
Europe, Canada, US, RoW
lapatinib, placebo
GlaxoSmithKline
Neoplasms, Breast
09/11
07/13
NCT00486954: Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark ASCO-GI 2013
Jan 2013 - Jan 2013: ASCO-GI 2013
Completed
3
273
Japan, RoW
Lapatinib, Lapatinib: Tykerb, Tyverb, Paclitaxel
GlaxoSmithKline
Neoplasms, Gastrointestinal Tract
01/12
10/12
NSABP B-41, NCT00486668: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Checkmark As neoadjuvant therapy for HER2-positive operable BC
Oct 2013 - Oct 2013: As neoadjuvant therapy for HER2-positive operable BC
Checkmark P3 data - ASCO
Jun 2012 - Jun 2012: P3 data - ASCO
Unknown status
3
529
Canada, US
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib
NSABP Foundation Inc, GlaxoSmithKline
Invasive Breast Cancer
06/12
03/17
NCT00820222: Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Checkmark P3 data - ESMO
Sep 2012 - Sep 2012: P3 data - ESMO
Checkmark P3 trial update
Dec 2011 - Dec 2011: P3 trial update
Completed
3
540
US, Europe, RoW
capecitabine, lapatinib, trastuzumab
Novartis Pharmaceuticals
Metastases, Brain
06/12
03/18
EMILIA, NCT00829166: A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark SABCS 2015
Nov 2015 - Nov 2015: SABCS 2015
Checkmark In pts with HER2-positive mBC & CNS mets
More
Completed
3
991
Europe, Canada, US, RoW
Trastuzumab emtansine, T-DM1, Trastuzumab-MCC-DM1, RO5304020, Lapatinib, Tykerb, Tyverb, Capecitabine, Xeloda
Hoffmann-La Roche
Breast Cancer
07/12
09/15
NCT00667251 / 2007-004568-27: Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark Data
May 2011 - May 2011: Data
Completed
3
652
Europe, Canada, Japan, US, RoW
trastuzumab, docetaxel, lapatinib ditosylate, paclitaxel
Novartis Pharmaceuticals, NCIC Clinical Trials Group
Breast Cancer
08/12
07/22
LOGiC, NCT00680901 / 2007-005725-29: - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Checkmark ESMO 2013
Sep 2013 - Sep 2013: ESMO 2013
Checkmark ASCO-2013
Jun 2013 - Jun 2013: ASCO-2013
Checkmark For advanced HER2-positive gastric cancer
More
Completed
3
545
Europe, Canada, US, RoW
Lapatinib, Tykerb, Placebo, Capecitabine, Oxaliplatin
Novartis Pharmaceuticals
Neoplasms, Gastrointestinal Tract
09/12
10/24
NCT00424255 / 2006-001623-18: Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
3
688
US, Canada, Europe, RoW
Lapatinib, Chemoradiation, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
03/13
11/13
NCT00688194 / 2007-006031-30: Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Unknown status
3
396
Europe
anastrozole, exemestane, fulvestrant, lapatinib ditosylate, letrozole, placebo
Gruppo Italiano Mammella (GIM)
Breast Cancer
05/13
 
ALTTO, NCT00490139 / 2006-000562-36: (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Checkmark From ALTTO trial for breast cancer (adjuvant)
Jul 2014 - Jul 2014: From ALTTO trial for breast cancer (adjuvant)
Checkmark From ALTTO trial for the treatment of HER2/ErbB2 positive primary breast cancer
More
Completed
3
8382
Europe, Canada, Japan, US, RoW
Lapatinib, Trastuzumab
Novartis Pharmaceuticals, North Central Cancer Treatment Group, National Cancer Institute (NCI), Breast International Group, Canadian Cancer Trials Group
Neoplasms, Breast
12/13
07/21
CALGB-40601, NCT00770809: Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark ASCO 2013
More
Active, not recruiting
3
305
US
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac
National Cancer Institute (NCI)
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
01/14
07/25
NCT00968968: Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P3 trial design - ASCO
Jun 2012 - Jun 2012: P3 trial design - ASCO
Checkmark P3 trial design
More
Terminated
3
37
Canada, US
Lapatinib, Trastuzumab
Novartis Pharmaceuticals
Cancer
02/14
03/18
NCT00390455: Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Checkmark Fulvestrant with or without lapatinib for postmenopausal women
Oct 2014 - Oct 2014: Fulvestrant with or without lapatinib for postmenopausal women
Checkmark Data
Dec 2010 - Dec 2010: Data
Completed
3
295
US
Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Placebo Administration
National Cancer Institute (NCI)
Estrogen Receptor Positive, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
07/14
07/14
CTRIAL-IE (ICORG) 11-10, NCT01526369: A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Completed
3
75
Europe, RoW
Trastuzumab, Paclitaxel, Lapatinib
Cancer Trials Ireland
Metastatic Breast Cancer
11/15
02/23
NCT00508274: Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

Checkmark Biomarker data
Apr 2011 - Apr 2011: Biomarker data
Terminated
3
52
RoW
lapatinib, LAP016, GW572016, capecitabine
Novartis Pharmaceuticals
Neoplasms, Breast
12/15
07/20
2004-001456-36: A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer. Studio di fase III, randomizzato, in aperto multicentrico mirato a confrontare GW572016 e capecitabina (Xeloda) verso Capecitabina in pazienti con carcinoma mammario avanzato o metastatico refrattario

Completed
3
20
Europe
Lapatinib, GW572016, XELODA*60CPR RIV 150MG, XELODA*60CPR RIV 150MG
GLAXO SMITHKLINE
Solid tumor treatment Trattamento tumori solidi
 
02/10
2011-005189-39: ICORG 11-10 (TH v THL) A study to find out whether combining lapatinib treatment with trastuzumab and paclitaxel is more effective at slowing the growth of HER2 positive metastatic breast cancer, than using trastuzumab and paclitaxel alone.

 
3
90
Europe
Lapatinib, Trastuzumab, Paclitaxel, GW5720126, Lapatinib, Herceptin, paclitaxel, Lapatinib, Herceptin, paclitaxel
ICORG, ICORG -All Ireland Cooperative Oncology Research Group, All Ireland Cooperative Oncology Research Group (ICORG), GlaxoSmithKline,
HER2 positive Metastatic Breast Cancer
 
 
NCT01160211 / 2010-019577-16: A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Checkmark ALTERNATIVE trial in HER2+ breast cancer
May 2017 - May 2017: ALTERNATIVE trial in HER2+ breast cancer
Checkmark P3 trial design - ASCO
Jun 2012 - Jun 2012: P3 trial design - ASCO
Checkmark P3 trial design
More
Completed
3
369
Europe, Canada, Japan, US, RoW
lapatinib, trastuzumab, Aromatase inhibitor
Novartis Pharmaceuticals, GlaxoSmithKline
Neoplasms, Breast
03/16
06/22
OVER, NCT02394496: Overcoming Endocrine Resistance in Metastatic Breast Cancer

Unknown status
3
396
Europe
Fulvestrant, Faslodex, Lapatinib, Aromatase Inhibitors, Aromatase Inhibitor, Placebo Lapatinib, Placebo
Consorzio Oncotech
Metastatic Breast Cancer
12/16
01/17
EPHOS-B, NCT01104571 / 2008-005466-30: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Checkmark P3 trial design
Dec 2011 - Dec 2011: P3 trial design
Active, not recruiting
3
257
Europe
trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis
Breast Cancer
08/17
09/25
2008-000673-38: A study to investigate the use of Lapatinib and Capecitabine together versus Trastuzumab and Capecitabine together to treat metastatic breast cancer.

Completed
3
650
Europe, RoW
Lapatinib, Trastuzumab, Capecitabine, GW572016, Film-coated tablet, Powder for solution for infusion, Tyverb, Herceptin, Xeloda
Novartis Pharma Services AG, GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline S.A., Novartis Pharma Services AG,
Metastatic breast cancer overexpressing ErbB2
 
 
NALA, NCT01808573 / 2012-004492-38: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Checkmark Data from NALA trial for HER2+ metastatic breast cancer at SABCS 2020
Dec 2020 - Dec 2020: Data from NALA trial for HER2+ metastatic breast cancer at SABCS 2020
Checkmark Pooled data from NALA, NEfERT-T and TBCRC 022 trials for HER2-positive breast cancer at SABCS 2019
Dec 2019 - Dec 2019: Pooled data from NALA, NEfERT-T and TBCRC 022 trials for HER2-positive breast cancer at SABCS 2019
Checkmark Data from NALA trial for HER2+ metastatic breast cancer at ASCO 2019 [screenshot]
More
Completed
3
621
Europe, Canada, Japan, US, RoW
neratinib, Nerlynx, capecitabine, Xeloda, lapatinib, Tykerb, Tyverb
Puma Biotechnology, Inc.
HER2+ Metastatic Breast Cancer (MBC)
09/18
12/19
BO29919, NCT03084939: Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Completed
3
351
RoW
Trastuzumab Emtansine, Kadcyla, Lapatinib, Capecitabine
Hoffmann-La Roche
Breast Cancer
11/18
03/23
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
PHOEBE, NCT03080805: Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer.

Unknown status
3
240
RoW
Pyrotinib Plus Capecitabine, Lapatinib Plus Capecitabine
Jiangsu HengRui Medicine Co., Ltd.
HER2 Positive Metastatic Breast Cancer
03/19
03/21
BAT-8001-002-CR, NCT04185649: The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Unknown status
3
410
RoW
BAT8001 for injection, Lapatinib, Lapatinib ditosylate tablets, Capecitabine, capecitabine tablets
Bio-Thera Solutions
HER2-positive Advanced Breast Cancer
07/20
12/21
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
ChiCTR1900027887: A clinical study for evaluating the efficacy and safety of BAT8001 injection for the treatment of HER2-positive advanced breast cancer

Recruiting
3
410
 
3.6 mg/kg, q3w, administered intravenously ;Lapatinib dose: Qd, 1250 mg/dose, administered on days 1-21 of each cycle; Capecitabine dose: Bid, 1000 mg/m2, administered on days 1-14 of each cycle, rest on days 15-21.
Sun Yat-sen University Cancer Center; Bio-thera Solutions, Ltd., Self-raised funds
HER-2 positive advanced breast cancer
 
 
DETECT III, NCT01619111 / 2010-024238-46: - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Completed
3
105
Europe
standard chemo- or endocrine therapy, standard chemo- or endocrine therapy + Lapatinib
Prof. Wolfgang Janni
HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells
01/22
01/22
NCT06313983: A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Recruiting
3
339
RoW
Hemay022+AI, Lapatinib+Capecitabine
Tianjin Hemay Pharmaceutical Co., Ltd
Breast Cancer
12/25
06/26
DESTINY-Breast02, NCT03523585 / 2018-000221-31: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread []

Hourglass Jan 2024 - Jun 2024 : Approval in EU for 3L HER2+ breast cancer (based on DESTINY-Breast02 trial)
Hourglass Jan 2022 - Dec 2022 : Acceptance of regulatory submission in US for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial)
Checkmark Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Checkmark Presentation of primary data from DESTINY-Breast02 trial for HER2 +ve breast cancer
More
Active, not recruiting
3
608
Europe, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Capecitabine, Investigator's Choice Comparative Therapy, Lapatinib, Trastuzumab
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
06/22
05/25
CTR20200806: Phase III study of TAA013 versus lapatinib combined with capecitabine in patients with HER2-positive breast cancer

Terminated
3
438
China
TAA013 - TOT Biopharm
Dong Yao Pharmaceutical Co., Ltd.
Locally advanced or metastatic HER2-positive breast cancer
 
 
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
Fillful-03, NCT05122494: A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer

Recruiting
3
339
RoW
Hemay022+AI, Lapatinib+Capecitabine
Tianjin Hemay Oncology Pharmaceutical Co., Ltd
Breast Cancer
02/24
06/24
ACE-Breast-02, CTR20201708: Clinical study evaluating ARX788 in the treatment of HER2-positive advanced breast cancer

Recruiting
2/3
440
China
capecitabine - Generic mfg., lapatinib - Generic mfg., anvatabart opadotin (ARX788) - Ambrx
Zhejiang Pharmaceutical Co., Ltd./Zhejiang Xinma Biopharmaceutical Co., Ltd.
HER2-positive breast cancer
 
 
GeparSixto, NCT01426880 / 2011-000553-23: Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Checkmark
Dec 2013 - Dec 2013: 
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark HER2-positive and triple negative breast cancer
More
Completed
2/3
595
Europe
Carboplatin, platin, background treatment, Avastin, Paclitaxel, Myocet, Lapatinib, Bevacizumab
German Breast Group, Teva Pharmaceuticals USA, Roche Pharma AG, GlaxoSmithKline
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Cancer
05/13
08/13
LaMB, NCT00949455 / 2007-001826-28: A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium

Unknown status
2/3
204
Europe
lapatinib ditosylate, Tykerb, Tyverb, Placebo
Queen Mary University of London, GlaxoSmithKline
Bladder Cancer
07/15
 
ST03, NCT00450203 / 2006-000811-12: Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Checkmark Data-ASCO
May 2011 - May 2011: Data-ASCO
Unknown status
2/3
1103
Europe
bevacizumab, capecitabine, cisplatin, Epirubicin, adjuvant therapy, conventional surgery, neoadjuvant therapy, Lapatinib, Tyverb
Professor David Cunningham, Cancer Research UK, Roche Pharma AG, GlaxoSmithKline
Oesophagogastric Cancer
12/17
12/17
NCT03085368: A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin

Unknown status
2/3
482
RoW
lapatinib/herceptin
Peking Union Medical College Hospital, Taizhou EOC Pharma Co., Ltd.
HER2-positive Breast Cancer
05/18
03/21
2008-005425-11: A Phase 2 Randomized Open Label Study of Neratinib versus Lapatinib plus Capecitabine for the treatment of ErbB-2 Positive Locally Advanced or Metastatic Breast Cancer

Completed
2/3
1283
Europe, RoW
neratinib, HKI-272, Film-coated tablet, XELODA, TYVERB
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426 USA, Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA, Puma Biotechnology, Inc, Wyeth Research, Wyeth Pharmaceuticals Inc., acting through its division Wyeth research, a Pfizer company, Wyeth Research Division of Wyeth Pharmaceutical Inc., Pfizer Inc, , Puma Biotechnology, Inc
Locally advanced or metastatic breast cancer, Locall advanced or metastatic breast cancer, Diseases [C] - Cancer [C04]
 
 
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24

Download Options